(Circulation. 2002;105:2130.)
© 2002 American Heart Association, Inc.
Editorial |
From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass.
Correspondence to Jane E. Freedman, MD, Boston University School of Medicine, 715 Albany St, W507, Boston, MA 02118. E-mail freedmaj@bu.edu
Key Words: Editorials atherosclerosis thrombosis leukocytes myocardial infarction
Thrombus formation within a coronary vessel is the precipitating event in unstable coronary syndromes. The angiographic severity of coronary stenoses may not predict sites of subsequent acute coronary events, inasmuch as rupture of atheromatous plaque with thrombosis in relatively mildly stenosed vessels may underlie many acute coronary syndromes. The intact endothelium normally prevents platelet activation, but the intimal injury associated with endothelial denudation and plaque rupture exposes subendothelial collagen and von Willebrand factor, which support prompt platelet adhesion and activation. Circulating platelets can adhere either directly to collagen or indirectly, via the binding of von Willebrand factor, to the glycoprotein Ib/IX complex. Local platelet activation promotes thrombus formation and additional platelet recruitment by supporting cell surface thrombin formation and releasing potent platelet agonists, such as adenosine 5'-diphosphate, serotonin, and thromboxane A2. The central role of platelet activation in acute coronary syndromes is supported by increased platelet-derived thromboxane and prostaglandin metabolites detected in patients with acute coronary syndromes1 and the clear clinical benefit of treatment with aspirin for prevention of acute coronary events.2
See p 2166
The importance of platelet-dependent thrombosis has made the platelet aggregate a common therapeutic target in acute coronary syndromes. Recently, such therapies have included the use of aspirin, thienopyridines, and direct glycoprotein IIb/IIIa inhibitors. Although the mechanism of action of these various agents differs, they all inhibit fibrinogen-dependent plateletplatelet associations (ie, platelet aggregation). However, as highlighted by the recent disappointing clinical results of trials using oral glycoprotein IIb/IIIa inhibitors,3 merely preventing the process of platelet
This article has been cited by other articles:
![]() |
A. J. Lucking, M. Lundback, N. L. Mills, D. Faratian, S. L. Barath, J. Pourazar, F. R. Cassee, K. Donaldson, N. A. Boon, J. J. Badimon, et al. Diesel exhaust inhalation increases thrombus formation in man Eur. Heart J., December 2, 2008; 29(24): 3043 - 3051. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Catellier, N. Aleksic, A. R. Folsom, and E. Boerwinkle Atherosclerosis Risk in Communities (ARIC) Carotid MRI Flow Cytometry Study of Monocyte and Platelet Markers: Intraindividual Variability and Reliability Clin. Chem., August 1, 2008; 54(8): 1363 - 1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brambilla, M. Camera, D. Colnago, G. Marenzi, M. De Metrio, P. L. Giesen, A. Balduini, F. Veglia, K. Gertow, P. Biglioli, et al. Tissue Factor in Patients With Acute Coronary Syndromes: Expression in Platelets, Leukocytes, and Platelet-Leukocyte Aggregates Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 947 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tamagawa-Mineoka, N. Katoh, E. Ueda, H. Takenaka, M. Kita, and S. Kishimoto The Role of Platelets in Leukocyte Recruitment in Chronic Contact Hypersensitivity Induced by Repeated Elicitation Am. J. Pathol., June 1, 2007; 170(6): 2019 - 2029. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood, September 15, 2006; 108(6): 1895 - 1902. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Armstrong, D. A. Morrow, and M. S. Sabatine Inflammatory Biomarkers in Acute Coronary Syndromes: Part IV: Matrix Metalloproteinases and Biomarkers of Platelet Activation Circulation, March 7, 2006; 113(9): e382 - e385. [Full Text] [PDF] |
||||
![]() |
B. P. O'Sullivan and A. D. Michelson The Inflammatory Role of Platelets in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 483 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Guessous, M. Marcinkiewicz, R. Polanowska-Grabowska, S. Kongkhum, D. Heatherly, T. Obrig, and A. R. L. Gear Shiga Toxin 2 and Lipopolysaccharide Induce Human Microvascular Endothelial Cells To Release Chemokines and Factors That Stimulate Platelet Function Infect. Immun., December 1, 2005; 73(12): 8306 - 8316. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Weyrich, M. M. Denis, J. R. Kuhlmann-Eyre, E. D. Spencer, D. A. Dixon, G. K. Marathe, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet-Monocyte Aggregates Circulation, February 8, 2005; 111(5): 633 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C.M. Appeldoorn, A. Bonnefoy, B. C.H. Lutters, K. Daenens, T. J.C. van Berkel, M. F. Hoylaerts, and E. A.L. Biessen Gallic Acid Antagonizes P-Selectin-Mediated Platelet-Leukocyte Interactions: Implications for the French Paradox Circulation, January 4, 2005; 111(1): 106 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. von Kanel and J. E. Dimsdale Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease Chest, November 1, 2003; 124(5): 1956 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ashman, M. G. Macey, S. L. Fan, U. Azam, and M. M. Yaqoob Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2088 - 2096. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.D. Garlichs, S. Kozina, S. Fateh-Moghadam, B. Tomandl, C. Stumpf, S. Eskafi, D. Raaz, A. Schmeisser, A. Yilmaz, J. Ludwig, et al. Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia Stroke, June 1, 2003; 34(6): 1412 - 1418. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Freedman CD40 Ligand -- Assessing Risk Instead of Damage? N. Engl. J. Med., March 20, 2003; 348(12): 1163 - 1165. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |